NDA 215390 · Teva
Igalmi
Dexmedetomidine Hydrochloride · Buccal, Sublingual · Central alpha-2 Adrenergic Agonist
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Apr 5, 2022
Approved uses
3
Original approval plus efficacy supplements
Registered trials
1,922
279 Phase 3, 159 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2026 Supplement 3 · Efficacy LabelLetter
- Nov 19, 2025 Supplement 2 · Efficacy LabelLetter
- Apr 5, 2022 Original approval · Type 3 - New Dosage Form LetterLabelReview
2 products under this application
- IGALMI · DEXMEDETOMIDINE HYDROCHLORIDE EQ 0.18MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription
- IGALMI · DEXMEDETOMIDINE HYDROCHLORIDE EQ 0.12MG BASE · FILM, BUCCAL, SUBLINGUAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dexmedetomidine" as an intervention, any sponsor and status, largest first.
- Perioperative Dexmedetomidine and Long-term Survival After Cancer SurgeryPivotal-lookingRecruiting
Peking University First HospitalAcademic, hospital or other
NCT06030804 · 4,532 participants (planned) · Start Sep 12, 2023 · Primary completion Sep 2027
Drug: Dexmedetomidine; Placebo · For: Elderly; Cancer Surgery; Dexmedetomidine and 1 more
Sites: Hefei, China; Beijing, China; Chongqing, China · 40 sites in all
- Intranasal Dexmedetomidine and Perioperative Myocardial Injury in Patients Having Percutaneous Coronary InterventionsPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT07847580 · 2,500 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 30, 2029
Drug: Intranasal dexmedetomidine; Normal Saline · For: Coronary Heart Disease; Coronary Artery Disease
Sites: Hangzhou, China
- Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery PatientsPivotal-lookingRecruiting
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT04289142 · 2,400 participants (planned) · Start Dec 1, 2019 · Primary completion Jul 2028
Drug: Dexmedetomidine Hydrochloride Group · For: Delirium; Cognitive Dysfunction; Cognition Disorder and 14 more
Sites: Vancouver, Canada; London, Canada; Toronto, Canada · 8 sites in all
- Perioperative Multimodal Analgesia Protocol for Supratentorial CraniotomyPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06406829 · 2,000 participants (planned) · Start Feb 9, 2026 · Primary completion Dec 31, 2026
Drug: Dexmedetomidine; Normal saline · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
- Perioperative Multimodal Analgesia for Supratentorial CraniotomyPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07441421 · 2,000 participants (planned) · Start Mar 9, 2026 · Primary completion Dec 31, 2027
Drug: Dexmedetomidine · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
Sites: Beijing, China
- Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576517 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2029
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 3 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After SurgeryPivotal-lookingNot yet recruiting
Peking University First HospitalAcademic, hospital or other
NCT07576543 · 1,996 participants (planned) · Start Oct 2026 · Primary completion Dec 2030
Drug: Dex-Esk; Placebo · For: Older Patients; Surgery; Dexmedetomidine and 4 more
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 6 sites in all
- Comparison of Epidural Labor Analgesia With Dexmedetomidine or SufentanilPivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT03622047 · 1,800 participants (planned) · Start Aug 15, 2018 · Primary completion Aug 1, 2020
Drug: Dexmedetomidine ropivacaine; No analgesia labor · For: Pharmacological Action
Sites: Shanghai, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Igalmi (Dexmedetomidine HCl)
2024 spending
$309K
Beneficiaries
42
97 claims
Per beneficiary
$7,357
$108.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $64,689 |
| 2024 | $308,999 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dexmedetomidine vs other sedatives in critically ill mechanically ventilated adults: a systematic review and meta-analysis of randomized trials.
Lewis K, Alshamsi F, Carayannopoulos KL, et al. · Intensive Care Med 2022 · Meta-Analysis, Systematic Review
- Dexmedetomidine for adult cardiac surgery: a systematic review, meta-analysis and trial sequential analysis.
Poon WH, Ling RR, Yang IX, et al. · Anaesthesia 2023 · Systematic Review, Meta-Analysis
- Dexmedetomidine for analgesia and sedation in newborn infants receiving mechanical ventilation.
Lim JY, Ker CJ, Lai NM, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Outcomes of dexmedetomidine versus propofol sedation in critically ill adults requiring mechanical ventilation: a systematic review and meta-analysis of randomised controlled trials.
Heybati K, Zhou F, Ali S, et al. · Br J Anaesth 2022 · Meta-Analysis, Systematic Review
- Efficacy of perioperative dexmedetomidine in postoperative pain and neurocognitive functions in orthopedic surgery: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
Zhang X, Leng Y, Yuan X, et al. · Int J Surg 2025 · Meta-Analysis, Systematic Review
- Pharmacological and non-pharmacological interventions to prevent delirium in critically ill patients: a systematic review and network meta-analysis.
Burry LD, Cheng W, Williamson DR, et al. · Intensive Care Med 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.